NOVO.B.DK

338.3

-2.38%↓

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

NOVO.B.DK

338.3

-2.38%↓

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

NOVO.B.DK

338.3

-2.38%↓

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

NOVO.B.DK

338.3

-2.38%↓

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

NOVO.B.DK

338.3

-2.38%↓

COLO.B.DK

625.8

+0.55%↑

GMAB.DK

1,759.5

+1.03%↑

ZEAL.DK

425.4

-4.9%↓

AMBUB.DK

98.4

+0.36%↑

Search

H Lundbeck A-S

Closed

41.9 1.6

Overview

Share price change

24h

Current

Min

40.56

Max

42.16

Key metrics

By Trading Economics

Income

-186M

966M

Sales

-212M

6B

P/E

Sector Avg

11.789

35.733

EPS

1.35

Dividend yield

2.29

Profit margin

16.039

Employees

5,700

EBITDA

811M

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.29%

3.13%

Market Stats

By TradingEconomics

Market Cap

5.9B

40B

Previous open

40.3

Previous close

41.9

H Lundbeck A-S Chart

Past performance is not a reliable indicator of future results.

Related News

9 Sept 2025, 23:37 UTC

Hot Stocks

Stocks to Watch: Oracle, Wearable Devices, GameStop

9 Sept 2025, 20:41 UTC

Earnings

Oracle's Backlog Surges With Major Customer Deals in 1Q

9 Sept 2025, 20:30 UTC

Earnings

GameStop 2Q Sales, Profit Rise

9 Sept 2025, 23:19 UTC

Market Talk

ANZ Adds a Further 50 Bps in FOMC Cuts to Outlook -- Market Talk

9 Sept 2025, 21:35 UTC

Earnings

Oracle Stock Soars on Strong AI Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 21:32 UTC

Earnings

Oracle's Backlog Swells With Big Customer Deals -- Update

9 Sept 2025, 21:02 UTC

Acquisitions, Mergers, Takeovers

DHL Adds to Healthcare Logistics Services With Acquisition -- Update

9 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 Sept 2025, 20:33 UTC

Earnings

These Stocks Moved the Most Today: Apple, UnitedHealth, Nebius, Wolfspeed, Tourmaline Bio, Albemarle, Dell, and More -- Barrons.com

9 Sept 2025, 20:26 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:23 UTC

Earnings

Oracle Stock Soars on Strong Backlog. Earnings Were Good Enough. -- Barrons.com

9 Sept 2025, 20:12 UTC

Earnings

Oracle Stock Jumps on Mixed Earnings Report -- Barrons.com

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects Cloud Infrastructure Rev to Grow 77% to $18 B This Fiscal Yr >ORCL

9 Sept 2025, 20:10 UTC

Earnings

Oracle Expects to Sign-Up Several Additional Multi-B-dollar Customers and RPO Is Likely to Exceed Half-A-Trillion Dollars Over Next Few Mos

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Adj EPS $2.76-Adj EPS $2.80 >SNPS

9 Sept 2025, 20:09 UTC

Earnings

Synopsys Sees 4Q Loss/Shr 16c-Loss 27c >SNPS

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Short-term Deferred Rev Were $12.1 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle 1Q Operating Income Was $4.3 B >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Oracle Expects MultiCloud Rev to Grow Substantially Every Qtr for Several Years >ORCL

9 Sept 2025, 20:08 UTC

Earnings

Synopsys Sees 4Q Rev $2.23B-$2.26B >SNPS

9 Sept 2025, 20:07 UTC

Earnings

Oracle Total Remaining Performance Obligations Up to $455 B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Software Revenue $5.72B >ORCL

9 Sept 2025, 20:06 UTC

Earnings

Synopsys 3Q Adj EPS $3.39 >SNPS

9 Sept 2025, 20:06 UTC

Earnings

Oracle 1Q Cloud Revenue $7.19B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Rev $14.93B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q EPS $1.01 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Synopsys 3Q EPS $1.50 >SNPS

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Services Revenue $1.35B >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Adj EPS $1.47 >ORCL

9 Sept 2025, 20:05 UTC

Earnings

Oracle 1Q Hardware Revenue $670M >ORCL

Peer Comparison

Price change

H Lundbeck A-S Forecast

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About H Lundbeck A-S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena/Abilify Maintena for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat MDD and schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat dementia; Onfi for epilepsy; Sabril for the treatment of refractory complex partial seizures and infantile spasms; Xenazine for chorea; Deanxit for depression; Cipramil for depression and anxiety; and Cisordinol to treat psychosis. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.
help-icon Live chat